Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of imlifidase plus standard of care versus standard of care alone in severe anti-GBM antibody disease
NL-OMON59408Phase 3Completed
- Sponsor
- Hansa Biopharma
- Start
- May 2023
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of imlifidase in anti-glomerular basement membrane disease, sponsored by Hansa Biopharma. Primary endpoint: Renal function at 6 months. Started May 2023; status: completed.
02
Drugs
imlifidase
03
Conditions
anti-glomerular basement membrane disease
Beyond the preview
Go deeper on NL-OMON59408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59408.